Ticker: TSX - TOS
Shares Outstanding: 46,244,102
QUEBEC CITY, June 11 /CNW Telbec/ -TSO3 Inc. ("TSO3") (TSX: TOS)
announces another sale of its 125L Ozone Sterilizer to an American hospital.
"Once again, the North American market is responding positively to the
introduction of our ozone sterilization technology," declared Jocelyn Vézina,
the Chief Executive Officer of TSO3 Inc.
"This additional sale illustrates the importance of having built our own
direct sales force to make the 125L Ozone Sterilizer a true success. We are
now beginning to see our sales efforts rewarded," he concluded.
TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in
1998. The Company's mission is to develop and market innovative and
comprehensive sterilization solutions. TSO3 has perfected an innovative
sterilization process using ozone as the sterilizing agent. The first product
based on this technological platform is the 125L Ozone Sterilizer, which is
intended for hospital sterilization units. The 125L - named after its
125- litre/4.3-cubic-foot capacity - was designed to sterilize heat-sensitive
surgical and diagnostic devices which are expensive and in high demand from
the surgical suite. The ozone sterilization process is a safe, efficacious,
fast and cost-effective response to evolving sterilization needs.
The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization
by Health Canada and by the U.S. Food and Drug Administration (FDA).
TSO3 currently has more than 60 employees, 23 of whom work in the sales
and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Mathieu Claise, Interim Director, Corporate
Communications and Investor Relations, (418) 651-0003, Ext. 237, firstname.lastname@example.org;
Source: TSO3 Inc.